Our mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil.
We are very pleased to be able to bring Suprax® an important anti-infective product in pediatric practice, back to the US market.
We are recognized as a leading manufacturer of cephalosporin API's, with FDA approval to manufacture complex oral and injectable cephalosporins.
Lupin is amongst the world's largest manufacturers of products in its chosen therapeutic areas.
LUPIN COMPLETES ACQUISTION OF PHARMA DYNAMICS, SOUTH AFRICA
Lupin Receives US FDA Approval for Generic Lumigan® Ophthalmic Solution 0.03%.
Lupin PR - Lupin Launches InspiraChamber Anti-Static Valved Holding Chamber Expands US Brands Portfolio
Lupin and Celon Announce Strategic Development and Licensing Agreement for Generic Advair Diskus®
Lupin Receives FDA Approval for Generic Vancocin® Capsules
Lupin launches Generic DIOVAN® Tablets
Lupin Receives Tentative Approval for Generic Prezista® Tablets
Lupin and Salix Announce Exclusive Distribution Agreement for Canada, ZaxineÂ®, RelistorÂ®
manufacturing / r&d
Copyright © 2010, Lupin Pharmaceuticals, Inc., All Rights Reserved.